Vinblastine Sulphate Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1mg/ml
Reference Brands:
Category:
Oncology Cancer Care
Product/Composition:-
Vinblastine Sulphate Injection
Strength:-
1mg/ml
Form:-
Injection
Production Capacity
1 Million Injection/Month
Vinblastine Sulphate is used for Lymphoma, Carcinoma, Sarcoma, Mycosis Fungoides, Choriocarcinoma and other conditions. vinblastine Sulphate is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: Hodgkin'S Disease, Lymphoma, Carcinoma.
Vinblastine Sulphate Injection is available in Injection
and strengths such as 1mg/ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vinblastine Sulphate Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vinblastine Sulphate Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
-
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing